Wake up lipolysis before you touch GH.
Most cutting protocols fail in the first ten days for the same reason: the user stacks a GH secretagogue on top of a metabolism that hasn't been told to release fat yet. The cell is still in storage mode. Insulin is sitting at fasting >8, mitochondria are inflamed, and the NAD+ pool is depleted. You inject CJC/Ipamorelin into that environment and the GH pulse hits a system that can't oxidize what gets liberated — you get water weight, bloat, and a flat scale. The substrate is explicit on this: GH secretagogues are contraindicated when fasting insulin is elevated, because they worsen insulin resistance in an already insulin-resistant cell. MOTS-c is contraindicated on inflamed mitochondria for the same reason — paradoxical response when the substrate isn't prepared.
Phase 1 is not weight loss. Phase 1 is metabolic priming. You are preparing the substrate so that the Phase 2 GH stack (introduced Week 5) lands on a cell that can actually use it.
What's actually happening at the cellular level
Three failures define a cell that won't release fat: high fasting insulin (storage-locked), low NAD+ availability (mitochondria can't run the salvage pathway), and depressed lipolytic signaling at the adipocyte. Standard caloric restriction alone does not fix any of these — long-term calorie restriction actually drops thyroid output, sympathetic tone, and metabolic rate, which is why post-diet rebound is the default outcome.
Phase 1 attacks all three failures simultaneously. AOD-9604 is a synthetic fragment of the C-terminal of human growth hormone (residues 176-191) — the lipolytic portion stripped of the glucose-disregulating portion. It binds adipocyte beta-3 receptors and activates hormone-sensitive lipase without elevating IGF-1, without affecting glucose tolerance, and without the muscle-building signaling of full-length GH. This is critical for the cutting phase: you want fat liberation without the appetite spike, without the water retention, and without anabolic signaling competing with the deficit.
5-Amino-1MQ addresses the NAD+ side. It is an oral small molecule that inhibits the NNMT enzyme. NNMT normally degrades NAD+ precursors as part of methylation; blocking it raises NAD+ availability in the adipocyte specifically, where NNMT is overexpressed in obesity. Practitioner consensus is that 5-Amino-1MQ paired with morning fasted training produces measurable lipolysis where caloric deficit alone stalls — the compound has been used by clinicians specifically before fasted morning workouts to push the cell into beta-oxidation. The substrate cites it as the "clean energy" companion to AOD: AOD liberates the fatty acid, 5-Amino-1MQ gives the mitochondria the NAD+ to burn it.
MOTS-c is the third lever, but it earns the third slot, not the first. MOTS-c is encoded in mitochondrial DNA and activates AMPK — it makes the cell "beg" for fuel by lowering ATP charge and forcing fatty acid oxidation. It works only if the mitochondria are prepared. On an inflamed mitochondrial substrate, it produces a paradoxical fatigue response. Hence the mito-preparedness step before introducing it, and the lower entry dose in Week 1.
The Phase 1 stack (Weeks 1-4)
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| AOD-9604 | 300 mcg | SubQ, near target fat | Daily, fasted AM | Expert | 12-week cycle, 4-week break. Inject 20-30 min before fasted training when possible. |
| 5-Amino-1MQ | 50-100 mg | Oral | Daily, AM | Expert | Take before fasted morning workout. Clean energy + lipolysis amplifier. Cycle 3 months on, 1 month off optional. |
| MOTS-c | 5 mg per week total (split 2-3 doses) | SubQ, lower abdomen | 2-3x/week | Clinical | Start at 5 mg/week total in Week 1. Can titrate toward 10 mg/week total by Week 4 if tolerated. |
| NMN (low-dose primer) | 10 mg | Oral | Daily, AM | Expert | Gentle NAD+ precursor. Pairs with 5-Amino-1MQ — NMN raises supply, 5-Amino-1MQ reduces waste. Net positive NAD+ balance. |
| Magnesium | [practitioner corpus thin on exact dose for this stack — track and report] | Oral | Daily | Expert | Cofactor for the 300+ enzymatic reactions including ATP synthesis that MOTS-c is asking the cell to run faster. |
Injection technique notes from the substrate: AOD-9604 is a systemic-and-local compound for fat loss — the practitioner pattern is to inject subcutaneously into the lower abdomen, 2 inches from the navel, alternating left and right, "grab a pinch, fire it in." Some clinicians inject near the target depot for theoretical local concentration; the substrate is split on whether this beats systemic dosing. Rotate sites in a clockwise pattern around the navel, staying at least 2 inches from the umbilicus to prevent lipodystrophy (hardened tissue) and bruising. Use 100-unit insulin syringes — for 300 mcg AOD from a 5 mg vial reconstituted with 2 mL bacteriostatic water, concentration is 2,500 mcg/mL, so 300 mcg = 0.12 mL = 12 units.
Timing matters. AOD and 5-Amino-1MQ both go in fasted, AM, before training if you train fasted. The substrate is clear on the mechanism: insulin suppresses fat oxidation. Eating carbohydrates before this stack neutralizes most of the work. Hold the fast through the injection window — water, electrolytes, black coffee are fine. First meal of the day comes after training.
What you should feel — Week by week
- Week 1: Mild appetite suppression by day 3-4. Energy in the morning training window noticeably cleaner — the 5-Amino-1MQ "clean energy" the substrate describes. No scale movement yet.
- Week 2: Waist measurement starts to drop before bodyweight does. Sleep often deepens. Possible mild fatigue on MOTS-c injection days as mitochondrial demand ramps — this is the AMPK signal, not a problem.
- Week 3: Visible flattening of the lower abdomen depot when AOD is injected locally. Scale begins to move 0.5-1 lb/week. Strength holds (this is the cutting-specific tell — Phase 1 is designed to preserve performance).
- Week 4: Steady recomposition. Pre-Phase-2 marker — you should now have improved metabolic flexibility, lower morning hunger, and a measurably tighter waist before introducing the GH secretagogue stack in Week 5.
What's NOT happening yet
- No GH pulse. No CJC, no Ipamorelin, no Tesamorelin, no MK-677 until Week 5. The substrate is explicit that stacking GH secretagogues onto an unprepared cell with high fasting insulin worsens insulin resistance. Phase 1 lowers fasting insulin first.
- No dramatic weight loss. This is not Retatrutide. This is not a GLP-1 protocol. Expect 2-4 lbs over Weeks 1-4. The mass loss curve steepens in Phase 2.
- No muscle gain. AOD-9604 does not raise IGF-1 — that is the entire point of using the 176-191 fragment instead of full GH. You preserve muscle through training and protein, not from the Phase 1 compounds.
- No hunger crash. If you are starving by noon, the deficit is too aggressive or the morning protein is too low. The peptides are not appetite suppressants in the GLP-1 sense.
- No need for MOTS-c titration if Week 1 produces fatigue. That is the signal that mitochondrial preparedness is incomplete. Hold the dose, do not advance.
Research describes this rhythm. Track waist, fasting insulin, and morning energy weekly. Adjust.